Nicholas Donoghoe - Jun 29, 2023 Form 3 Insider Report for AbbVie Inc. (ABBV)

Role: EVP, Chief Bus/Strat Officer
Signature: T.O. Odutayo, attorney-in-fact for Nicholas J. Donoghoe
Stock symbol: ABBV
Transactions as of: Jun 29, 2023
Transactions value $: $0
Form type: 3
Date filed: 7/10/2023, 05:04 PM
Next filing: Dec 28, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ABBV	Common Stock, $0.01 par value						58.8K	Jun 29, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ABBV	Option (Right to buy)							Jun 29, 2023	Common Stock	32.7K	$79.02	Direct	F1
holding	ABBV	Option (Right to buy)							Jun 29, 2023	Common Stock	72K	$93.50	Direct	F2
holding	ABBV	Option (Right to buy)							Jun 29, 2023	Common Stock	29.8K	$105.92	Direct	F3
holding	ABBV	Option (Right to buy)							Jun 29, 2023	Common Stock	21.5K	$144.54	Direct	F4
holding	ABBV	Option (Right to buy)							Jun 29, 2023	Common Stock	17.6K	$149.62	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 10,904 shares on 02/21/2020, as to 10,903 shares on 02/21/2021, and as to 10,903 shares on 02/21/2022.
F2	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 24,005 shares on 02/20/2021, as to 24,004 shares on 02/20/2022, and as to 24,004 shares on 02/20/2023.
F3	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 9,938 shares on 02/18/2022 and as to 9,938 shares on 02/18/2023, and will become exercisable as to as to 9,937 shares on 02/18/2024.
F4	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,151 shares on 02/17/2023, and will become exercisable as to 7,151 shares on 02/17/2024 and as to 7,151 shares on 02/17/2025.
F5	Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 5,852 shares on 02/16/2024, as to 5,852 shares on 02/16/2025 and as to 5,851 shares on 02/16/2026.